Posted on March 06, 2020
"The cancer drug paclitaxel and a suppressive regimen of antiretroviral therapy (ART) is an effective treatment for AIDS-related Kaposi’s sarcoma, according to researchers who conducted a clinical trial comparing three chemotherapy regimens in combination with ART in people with advanced AIDS-Kaposi’s sarcoma in Africa and South America. The full findings, published online today in The Lancet, affirmed conclusions from interim data released when the trial ended early in March 2018."
"The randomized Phase 3 trial, known as ACTG A5263 and AMC-066, was funded by the National Institute of Allergy and Infectious Diseases (NIAID) and the National Cancer Institute (NCI) and conducted by the AIDS Clinical Trial Group (ACTG) with the AIDS Malignancy Consortium."
"Kaposi's sarcoma (KS) is a cancer that causes abnormal tissue to grow in the skin, the lining of the mouth and throat, lymph nodes, and the lungs and other internal organs. Since the development of ART, the number of KS cases has fallen dramatically in North America and Europe. However, KS remains common in other parts of the world, in part because ART availability and accessibility may be less comprehensive. This prevalence makes the study of KS critical to improving AIDS survival rates and informing the knowledge base for HIV and cancer research."